Under the renewed agreement, Orthofix will continue its exclusive marketing of the Trinity allograft product line through 2023, according to a May 3 news release. Orthofix will also continue working with MTF Biologics on the development of a demineralized bone matrix.
The bone matrix, called the Legacy DBM, will complement Orthofix’s demineralized bone line, which includes FiberFuse.
“This agreement solidifies our partnership with MTF Biologics as the sole provider of MTF allograft offerings,” Orthofix President of Global Spine Kevin Kenny said in the release. “The addition of the Legacy demineralized bone line will expand our biologic portfolio, increasing the options available and offering a value solution for our customers and their patients.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
